Lifestyle drugs: issues for debate.
Lexchin
J
J
Emergency Department, Toronto Hospital, Department of Family and Community Medicine, University of Toronto, Toronto, Ont. joel.lexchin@utoronto.ca
D000329:Advertising; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D002170:Canada; D003659:Decision Making, Organizational; D004345:Drug Industry; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005260:Female; D015276:Health Care Rationing / Q000458:organization & administration; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008019:Life Style; D008297:Male; D009313:National Health Programs / Q000458:organization & administration; D009765:Obesity / Q000188:drug therapy*; D000077403:Orlistat; D018579:Patient Selection; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data* / Q000639:trends; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
D019440:Anti-Obesity Agents; D007783:Lactones; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000077403:Orlistat; D000068677:Sildenafil Citrate